Results 41 to 50 of about 120,898,698 (232)

A cyclosporin A-sensitive mitochondrial pore [PDF]

open access: yes, 1993
Cyclosporin-A is a potent immunosuppressant used to prevent graft rejection. Work in this laboratory has suggested a novel action of cyclosporin, namely protection against the cell injury caused by energy deprivation e.g.
McGuinness, Orla Mary
core   +1 more source

THE EFFICACY OF CYCLOSPORIN A TREATMENT IN CASES WITH PRIMARY GLOMERULONEPHRITIS THAT ARE UNRESPONSIVE TO CONVENTIONAL IMMUNSUPRESSIVE THERAPY

open access: yesTurkish Journal of Nephrology, 2019
Immune system activation play an important role in the pathogenesis of primary glomerulonephritis. Although various immunsupressive agents have been used in the treatment of primary glomerulonephritis, still there is not an efficacious therapy model.
Mustafa GÜLLÜLÜ   +8 more
doaj  

Analysis of proliferative activity in oral gingival epithelium in immunosuppressive medication induced gingival overgrowth

open access: yesHead & Face Medicine, 2006
Background Drug-induced gingival overgrowth is a frequent adverse effect associated principally with administration of the immunosuppressive drug cyclosporin A and also certain antiepileptic and antihypertensive drugs.
Özdemir B Handan   +3 more
doaj   +1 more source

Epiphora: A Structured Diagnostic Approach for the Otolaryngologist

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Introduction Epiphora, or excessive tearing, has historically been predominantly managed by ophthalmologists. However, as there is substantial overlap between ophthalmic and otolaryngologic anatomy and pathology that may contribute to epiphora, patients with this symptom often present to otolaryngologists as well.
Luke M. O'Neil   +7 more
wiley   +1 more source

Papular dermatitis: response to cyclosporin

open access: yes, 2000
BACKGROUND/AIM: Papular dermatitis is a persistent pruritic papular dermatitis, often refractory to treatment. The objective was to examine the effectiveness of cyclosporin for the treatment of this condition.
Hendi, A   +7 more
core   +1 more source

Cyclosporin A in steroid-sensitive nephrotic syndrome with frequent relapses [PDF]

open access: yes, 1987
Eight patients with steroid-sensitive nephrotic syndrome which frequently relapsed despite cyclophosphamide treatment were given cyclosporin A (7.5 mg/kg/day to 10 mg/kg/day) for 8 to 12 weeks.
I K P Cheng   +3 more
core   +1 more source

Hypertrichosis: the possible side effect of cyclosporin in an infant with hemophagocyticlymphohistiocytosis receiving HLH-2004 chemotherapy protocol

open access: yesTurkish Journal of Hematology, 2009
Hemophagocyticlymphohistiocytosis is a life-threatening condition of severe hyperinflammation that results from an uncontrolled proliferation of activated lymphocytes and histiocytes secreting high amounts of inflammatory cytokines.
Sinem Akgül   +4 more
doaj  

Open-label non-blinded cohort study on anti-histaminic resistant chronic idiopathic urticaria in Western India

open access: yesIndian Journal of Dermatology, 2022
Introduction: Chronic idiopathic urticaria (CIU) is a chronic relapsing disease with hives for a period of six weeks or more. It has a significant impact on the physical and mental well-being of patients. Aims and Objectives: Open-label non-blinded study
Subramanian Natarajan   +1 more
doaj   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real‐World Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy